SCD and synucleinopathy: Notably, due to the protective effects of SCD1 inhibition observed in models of synucleinopathies, SCD1 may serve as a promising therapeutic target for other diseases characterized by pathogenic α-syn accumulations, such as dementia with Lewy bodies (DLB) and multiple system atrophy.